Floatz logo

(8S)-8-ETHYL-2,3-DIHYDRO-8-HYDROXY-15-((4-METHYL-1-PIPERAZINYL)METHYL)-11H-P-DIOXINO(2,3-G)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-9,12(8H,14H)-DIONE

Fallopian Tube Cancer

NCIC Clinical Trials GroupSmall moleculePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
65/ 100

Competitive context

125 Active assets in the Fallopian Tube Cancer cohort.

Asset / SponsorPhaseRating
Mirvetuximab Soravtansine
AbbVie
Phase 3BB
Inno-206
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BB
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Carboplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3BB
Hycamtin
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

(8S)-8-ETHYL-2,3-DIHYDRO-8-HYDROXY-15-((4-METHYL-1-PIPERAZINYL)METHYL)-11H-P-DIOXINO(2,3-G)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-9,12(8H,14H)-DIONE is also rated in:

primary peritoneal carcinomaDormant
B
Indicative ·
57 / 100
View asset →
Carcinoma, Small CellDormant
B
Indicative ·
57 / 100
View asset →
small cell lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →